CanSino Biologics (6185) Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6185 from our risk checks.
6185 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$44.28 |
| 52 Week High | HK$56.55 |
| 52 Week Low | HK$25.25 |
| Beta | 1.27 |
| 1 Month Change | -10.55% |
| 3 Month Change | 1.21% |
| 1 Year Change | 56.47% |
| 3 Year Change | -51.87% |
| 5 Year Change | -72.51% |
| Change since IPO | 27.61% |
Recent News & Updates
Recent updates
CanSino Biologics Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Oct 29
CanSino Biologics Inc. (HKG:6185) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 24Improved Revenues Required Before CanSino Biologics Inc. (HKG:6185) Stock's 26% Jump Looks Justified
Aug 04Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Mar 25Optimistic Investors Push CanSino Biologics Inc. (HKG:6185) Shares Up 26% But Growth Is Lacking
Feb 19CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%
Nov 11Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?
Jun 20The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Shareholder Returns
| 6185 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 4.4% | -3.4% | 1.6% |
| 1Y | 56.5% | 113.0% | 33.1% |
Return vs Industry: 6185 underperformed the Hong Kong Biotechs industry which returned 113% over the past year.
Return vs Market: 6185 exceeded the Hong Kong Market which returned 33.1% over the past year.
Price Volatility
| 6185 volatility | |
|---|---|
| 6185 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6185's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,115 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| 6185 fundamental statistics | |
|---|---|
| Market cap | HK$15.65b |
| Earnings (TTM) | -HK$155.38m |
| Revenue (TTM) | HK$1.06b |
Is 6185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6185 income statement (TTM) | |
|---|---|
| Revenue | CN¥971.83m |
| Cost of Revenue | CN¥250.33m |
| Gross Profit | CN¥721.50m |
| Other Expenses | CN¥863.53m |
| Earnings | -CN¥142.03m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 74.24% |
| Net Profit Margin | -14.62% |
| Debt/Equity Ratio | 28.7% |
How did 6185 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 16:35 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CanSino Biologics Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Hangci Zheng | China International Capital Corporation Limited |
| Yizheng Yang | China International Capital Corporation Limited |